Cost-effectiveness analysis of lumacaftor and ivacaftor combination for the treatment of patients with cystic fibrosis in the United States-Reference-Cited by-同舟云学术

Cost-effectiveness analysis of lumacaftor and ivacaftor combination for the treatment of patients with cystic fibrosis in the United States

Published:2018-09-29 Issue:1 Volume:13 Page:
ISSN:1750-1172
Container-title:Orphanet Journal of Rare Diseases
language:en
Short-container-title:Orphanet J Rare Dis

Author:

Sharma Dolly,Xing Shan,Hung Yu-Ting,Caskey Rachel N.,Dowell Maria L.,Touchette Daniel R.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Genetics (clinical),General Medicine

Link

http://link.springer.com/content/pdf/10.1186/s13023-018-0914-3.pdf

Reference35 articles.

1. FDA Briefing Document. Pulmonary-allergy drugs advisory Committee meeting. 2015. https://www.fdanews.com/ext/resources/files/05-15/05-11-15-CFbriefing.pdf?1515922386 . Accessed 21 August 2016.

2. Annual Data Report. Cystic Fibrosis Foundation Patient Registry. 2015. https://www.cff.org/Our-Research/CF-Patient-Registry/2015-Patient-Registry-Annual-Data-Report.pdf . Accessed 9 February 2016.

3. MacKenzie T, Gifford A, Sabadosa K, Quinton H, Knapp E, Goss C, et al. Longevity of patients with cystic fibrosis in 2000 to 2010 and beyond: survival analysis of the Cystic Fibrosis Foundation patient registry. Ann Intern Med. 2014;161:233–41.

4. Drugs@FDA: FDA Approved Drug Products. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&applno=206038 . Accessed 17 January 2016.

5. Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, et al. Lumacaftor-Ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med. 2015;373:220–31.

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Are We Capturing the Socioeconomic Burden of Rare Genetic Disease? A Scoping Review of Economic Evaluations and Cost-of-Illness Studies;PharmacoEconomics;2023-08-18

2. Liquid chromatographic determination of lumacaftor in the presence of ivacaftor and identification of five novel degradation products using high‐performance liquid chromatography ion trap time‐of‐flight mass spectrometry;Journal of Separation Science;2023-07-06

3. Access to effective but expensive treatments: An analysis of the solidarity argument in discussions on funding of medical treatments;Bioethics;2022-11-07

4. Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: From a US Third Party Payer Perspective;PharmacoEconomics;2022-06-13

5. Cost-Effectiveness Analysis of Fourth- or Further-Line Ripretinib in Advanced Gastrointestinal Stromal Tumors;Frontiers in Oncology;2021-12-06